Olympus continues medtech’s divestmania

Healthcare companies streamlining their businesses through divestments has been the most obvious trend of 2022, and the latest group following the craze is Olympus. The group is to sell its microscopy division, Evident, to Bain Capital for ¥427.6bn ($3.1bn) – its biggest ever divestment. Evident is not strictly medtech. The microscopes it makes are used for academic and clinical research, including drug discovery, as well as production of semiconductors and electronic components for the automotive and aviation sectors, among others. The move is part of Olympus’s plan to become a pure-play medtech group – it sold its digital camera business at the start of last year, and has since divested its regenerative medicine and IT units. The other aspect of the refocusing is acquisitions, Olympus told Evaluate Vantage in 2020, but the group has not been hugely active here, its largest acquisition for more than a decade being that of the interventional pulmonology specialist Veran Medical Technologies for $340m in late 2020. Perhaps after it shifts Evident, Olympus will be freer to do more meaningful deals. 

Healthcare divestmania: IPOs vs private equity
Parent Unit/new company Type of deal Focus Date
Pfizer Meridian Medical Technologies  Sale to private equity (Altaris Capital Partners) Autoinjectors Jan 24, 2022
Zimmer Biomet Zimvie Spinout via IPO Dental and spinal Mar 1, 2022
Becton Dickinson Embecta Spinout via IPO Diabetes Apr 1, 2022
Enovis^ Esab Spinout via IPO Fabrication technology Apr 5, 2022
Bausch Health Bausch + Lomb Spinout via IPO Ophthalmology May 6, 2022
GSK Haleon Spinout via IPO Consumer care Jul 18, 2022
Bayer Environmental science professional business Sale to private equity (Cinven) Environmental Expected H2 2022
Olympus Evident Sale to private equity (Bain Capital) Microscopy Expected Jan 4, 2023
Perkinelmer* Applied, food and enterprise services businesses** Sale to private equity (New Mountain Capital) Diagnostics Expected Q1 2023
General Electric GE Healthcare Spinout via IPO Medtech Expected early 2023
Johnson & Johnson As-yet unnamed Spinout via IPO Consumer care Expected mid-2023
3M As-yet unnamed Spinout via IPO Medtech Expected 2023
^Colfax spun off Esab, its fabrication business, then changed its name to Enovis. *Perkinelmer will change its name once the divestment is complete. **To be renamed Perkinelmer. Source: Evaluate Medtech & company communications.

Share This Article